Black Diamond Therapeutics (BDTX) Expected to Post Quarterly Earnings on Thursday

Black Diamond Therapeutics (NASDAQ:BDTX) will likely be announcing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 9:30 AM ET.

Black Diamond Therapeutics (NASDAQ:BDTX) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.02. On average, analysts expect Black Diamond Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Black Diamond Therapeutics Trading Down 5.7%

NASDAQ:BDTX opened at $1.66 on Thursday. The firm has a market capitalization of $95.12 million, a PE ratio of -2.16 and a beta of 3.25. Black Diamond Therapeutics has a 1 year low of $1.60 and a 1 year high of $4.94. The firm’s fifty day simple moving average is $1.93 and its 200 day simple moving average is $2.31.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BDTX. nVerses Capital LLC bought a new stake in shares of Black Diamond Therapeutics in the 4th quarter valued at approximately $26,000. Hudson Bay Capital Management LP bought a new position in shares of Black Diamond Therapeutics during the 2nd quarter worth approximately $26,000. Cerity Partners LLC bought a new position in shares of Black Diamond Therapeutics during the 2nd quarter worth approximately $26,000. Stokes Family Office LLC acquired a new stake in Black Diamond Therapeutics in the 4th quarter valued at $27,000. Finally, American Century Companies Inc. acquired a new stake in Black Diamond Therapeutics in the 2nd quarter valued at $30,000. Institutional investors own 95.47% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on BDTX shares. Wall Street Zen downgraded Black Diamond Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Raymond James Financial reaffirmed an “outperform” rating on shares of Black Diamond Therapeutics in a report on Friday, May 22nd. HC Wainwright reiterated a “buy” rating on shares of Black Diamond Therapeutics in a report on Friday, May 22nd. BTIG Research increased their price objective on Black Diamond Therapeutics from $10.00 to $11.00 and gave the company a “buy” rating in a research report on Wednesday, April 29th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Black Diamond Therapeutics in a research report on Friday, May 22nd. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Black Diamond Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $9.83.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc is a precision oncology company focused on the discovery and development of small-molecule therapies that selectively target oncogenic proteins bearing tumor-driving mutations. Leveraging its proprietary Genetic Defined Allosteric (GDA) therapeutic platform, the company aims to identify unique allosteric binding sites in mutant proteins and engineer highly selective inhibitors. Headquartered in Cambridge, Massachusetts, Black Diamond applies structure-based drug design and molecular modeling to advance personalized cancer treatments.

The company’s development pipeline includes lead candidate BDTX-189, an allosteric inhibitor of mutant HER2, as well as programs directed at clinically relevant EGFR and KRAS mutations.